Alterity Therapeutics Files 6-K, Incorporates Presentations
Ticker: PRNAF · Form: 6-K · Filed: Oct 2, 2025 · CIK: 1131343
| Field | Detail |
|---|---|
| Company | Alterity Therapeutics Ltd (PRNAF) |
| Form Type | 6-K |
| Filed Date | Oct 2, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: filing, registration-statement, procedural
Related Tickers: ATHE
TL;DR
Alterity Therapeutics (ATHE) filed a 6-K, incorporating presentations into its S-8/F-3 filings. Standard procedural update.
AI Summary
Alterity Therapeutics Ltd. filed a Form 6-K on October 2, 2025, to incorporate by reference into several of its Registration Statements on Form S-8 and Form F-3. The filing includes Exhibit 99.1, which details Alterity's plans to deliver multiple presentations.
Why It Matters
This filing is procedural, incorporating previous disclosures into ongoing registration statements, which is relevant for investors tracking the company's regulatory filings and ongoing capital-raising activities.
Risk Assessment
Risk Level: low — This filing is a routine procedural update and does not contain new material financial information or significant business developments.
Key Players & Entities
- Alterity Therapeutics Ltd. (company) — Registrant
- Form 6-K (document) — Filing type
- October 2, 2025 (date) — Filing date
- Form S-8 (document) — Incorporated into
- Form F-3 (document) — Incorporated into
- Exhibit 99.1 (document) — Included exhibit
FAQ
What is the purpose of this Form 6-K filing?
The Form 6-K is being incorporated by reference into Alterity Therapeutics' Registration Statements on Form S-8 and Form F-3.
What is included in this filing?
The filing includes Exhibit 99.1, which states that Alterity Therapeutics will deliver multiple presentations.
What is the filing date of this report?
The filing date is October 2, 2025.
Which registration statements is this 6-K being incorporated into?
This 6-K is being incorporated into Registration Statements on Form S-8 (Files No. 333-251073, 333-248980 and 333-228671) and Form F-3 (Files No. 333-274816, 333-251647, 333-231417 and 333-250076).
What is the principal executive office address of Alterity Therapeutics?
The principal executive office is located at Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia.
Filing Stats: 193 words · 1 min read · ~1 pages · Grade level 12.4 · Accepted 2025-10-02 06:26:02
Filing Documents
- ea0259883-6k_alterity.htm (6-K) — 13KB
- ea025988301ex99-1_alterity.htm (EX-99.1) — 24KB
- ex99-1_001.jpg (GRAPHIC) — 14KB
- 0001213900-25-094961.txt ( ) — 58KB
From the Filing
OF FOREIGN PRIVATE ISSUER SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2 2025 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F This Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073 , 333-248980 and 333-228671 ) and our Registration Statements on Form F-3 (Files No. 333-274816 , 333-251647 , 333-231417 and 333-250076 ) ALTERITY THERAPEUTICS LIMITED (a development stage enterprise) The following exhibits are submitted: 99.1 Alterity to Deliver Multiple Presentations at MDS Conference 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Alterity Therapeutics Limited By: /s/ Geoffrey P. Kempler Geoffrey P. Kempler Chairman Date: October 2, 2025 2